Stock Events

Stock Events

X4 Pharmaceuticals 

€0
65
+€0+0% Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

30AprExpected
Q1 2025
Q2 2025
Q3 2025
Next
-3.38
-2.24
-1.1
0.04
Expected EPS
-0.17151400000000003
Actual EPS
N/A

Financials

-1,449.47%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
4.88MRevenue
-70.79MNet Income

Analyst Ratings

$6.83Average Price Target
The highest estimate is 9.11.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 48Q0.F. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap111.43B
Vertex Pharmaceuticals is a competitor because it also focuses on developing treatments for serious genetic diseases, similar to X4 Pharmaceuticals' focus on rare diseases.
Gilead Sciences
GILD
Mkt Cap173.41B
Gilead Sciences competes in the biopharmaceutical space, particularly in areas like HIV and liver diseases, which may overlap with X4 Pharmaceuticals' therapeutic areas.
Regeneron Pharmaceuticals
REGN
Mkt Cap80.54B
Regeneron Pharmaceuticals is involved in developing drugs for a variety of diseases, including rare genetic conditions, making it a competitor to X4 Pharmaceuticals.
Biogen
BIIB
Mkt Cap26.03B
Biogen competes with X4 Pharmaceuticals in the area of neurological diseases and has a focus on innovative therapies, potentially overlapping in treatment approaches.
AMGEN
AMGN
Mkt Cap187.56B
Amgen focuses on human therapeutics, including treatments for serious illnesses, which could compete with X4 Pharmaceuticals' rare disease treatments.
Incyte
INCY
Mkt Cap19.09B
Incyte Corporation works on small molecule drugs for oncology and inflammation, areas that may intersect with X4 Pharmaceuticals' research interests.
Alnylam Pharmaceuticals
ALNY
Mkt Cap42.29B
Alnylam Pharmaceuticals focuses on RNAi therapeutics for rare genetic diseases, directly competing with X4 Pharmaceuticals' rare disease portfolio.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.67B
BioMarin Pharmaceutical targets rare genetic diseases with its enzyme replacement therapies, making it a direct competitor to X4 Pharmaceuticals.
CRISPR Therapeutics
CRSP
Mkt Cap4.75B
CRISPR Therapeutics is engaged in gene editing technologies, which could offer treatments for the same rare diseases targeted by X4 Pharmaceuticals.

About

X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase Ib clinical trial to treat chronic neutropenia and Waldenström macroglobulinemia. The company is also developing X4P-002, a CXCR4 antagonist for the treatment of brain cancers; and X4P-003, a CXCR4 antagonist for the treatment of CXCR4 disorders and primary immunodeficiencies. It has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company was founded in 2010 and is headquartered in Boston, Massachusetts.
Show more...
CEO
ISIN
US98420X2027
WKN
000A3E4QR

Listings

F
DE
48Q0.F
XNAS
US
XFOR
BOATS
BOATS
XFOR.BOATS

0 Comments

Share your thoughts

FAQ

What is X4 Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange X4 Pharmaceuticals stocks are traded under the ticker 48Q0.F.
Is X4 Pharmaceuticals stock price growing?▼
48Q0.F stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year X4 Pharmaceuticals has showed a -14.18% decrease.
When is the next X4 Pharmaceuticals earnings date?▼
X4 Pharmaceuticals is going to release the next earnings report on April 30, 2026.
What were X4 Pharmaceuticals earnings last quarter?▼
48Q0.F earnings for the last quarter are -0.6 EUR per share, whereas the estimation was -0.44 EUR resulting in a -36.63% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is X4 Pharmaceuticals revenue for the last year?▼
X4 Pharmaceuticals revenue for the last year amounts to 4.88M EUR.
What is X4 Pharmaceuticals net income for the last year?▼
48Q0.F net income for the last year is -70.79M EUR.
When did X4 Pharmaceuticals complete a stock split?▼
The last stock split for X4 Pharmaceuticals was on April 28, 2025 with a ratio of 1:30.